[Federal Register Volume 68, Number 88 (Wednesday, May 7, 2003)]
[Rules and Regulations]
[Pages 24347-24349]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-11285]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 310 and 358
[Docket No. 02N-0359]
RIN 0910-AA01
Ingrown Toenail Relief Drug Products for Over-the-Counter Human
Use
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is issuing a final rule
establishing conditions under which over-the-counter (OTC) ingrown
toenail relief drug products containing sodium sulfide 1 percent in a
gel vehicle are generally recognized as safe and effective and not
misbranded. This rule also amends the regulation that lists
nonmonograph active ingredients in OTC drug products for ingrown
toenail relief by removing sodium sulfide from that list. This final
rule is part of FDA's ongoing review of OTC drug products.
DATES: This rule is effective June 6, 2003.
FOR FURTHER INFORMATION CONTACT: Gerald M. Rachanow, Center for Drug
Evaluation and Research (HFD-560), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-2307.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of September 9, 1993 (58 FR 47602), FDA
published a final rule establishing that any ingrown toenail relief
drug product for OTC human use is not generally recognized as safe and
effective and is misbranded. (See 21 CFR 310.538.) In that final rule,
sodium sulfide 1 percent was considered effective but not safe for the
temporary relief of pain associated with ingrown toenails because of
its potential for causing adverse reactions, particularly burning
sensations and skin irritation.
In the Federal Register of October 4, 2002 (67 FR 62218), after
reviewing new data that had been submitted, FDA proposed to establish
conditions under which OTC ingrown toenail relief drug products
containing sodium sulfide 1 percent in a gel vehicle are generally
recognized as safe and effective and not misbranded. The product is
used with a retainer ring to keep the product at the area of
application. The agency also proposed to amend the regulation (21 CFR
310.538) that lists nonmonograph active ingredients in OTC drug
products for ingrown toenail relief by removing sodium sulfide from
that list.
II. Comments Received in Response to the Proposal
In response to the proposal, the agency received two comments,
which are on public display in the Dockets Management Branch (HFA-305),
Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville,
MD 20852. One comment, from a drug manufacturer, supported the agency's
proposals and requested that the agency's review of the comments and
publication of the final rule be completed as expeditiously as
possible. The second comment, from a consumer, stated that the use of
the product with a ``restraining'' ring as indicated should have a
``green light.'' The comment added that there are many people who
experience the pain of an ingrown toenail, and that these products will
help.
III. The Agency's Final Conclusions
The agency concludes that the data support OTC drug monograph
status for 1 percent sodium sulfide in a gel vehicle applied topically
for the relief of discomfort (pain) of ingrown toenail. The product is
used with a retainer ring to keep the product at the area of
application. Accordingly, the agency is proposing a new monograph in
part 358, subpart D (21 CFR part 358, subpart D) for ingrown toenail
relief drug products that includes 1 percent sodium sulfide gel. The
agency is also amending Sec. 310.538 to state that it no longer
applies to sodium sulfide.
Mandating warnings in an OTC drug monograph does not require a
finding that any or all of the OTC drug products covered by the
monograph actually caused an adverse event, and FDA does not so find.
Nor does FDA's requirement of warnings repudiate the prior OTC drug
monographs and monograph rulemakings under which the affected drug
products have been lawfully marketed. Rather, as a consumer protection
agency, FDA has determined that warnings are necessary to ensure that
these OTC drug products continue to be safe and effective for their
labeled indications under ordinary conditions of use as those terms are
defined in the Federal Food, Drug, and Cosmetic Act. This judgment
balances the benefits of these drug products against their potential
risks (see 21 CFR 330.10(a)).
FDA's decision to act in this instance need not meet the standard
of proof required to prevail in a private tort action (Glastetter v.
Novartis Pharmaceuticals, Corp., 252 F.3d 986, 991 (8th Cir. 2001)). To
mandate warnings, or take similar regulatory action, FDA need not show,
nor do we allege, actual causation. For an expanded discussion of case
law supporting FDA's authority to require such warnings, see Labeling
of Diphenhydramine-Containing Drug Products for Over-the-Counter Human
Use, Final Rule (67 FR 72555, December 6, 2002).
IV. Analysis of Impacts
FDA has examined the impacts of this final rule under Executive
Order 12866, the Regulatory Flexibility Act (5 U.S.C. 601-612), and the
Unfunded Mandates Reform Act of 1995 (2 U.S.C. 1501 et seq.). Executive
Order 12866 directs agencies to assess all costs and benefits of
available regulatory alternatives and, when regulation is necessary, to
select regulatory approaches that maximize net benefits (including
potential economic, environmental, public health and safety, and other
advantages; distributive impacts; and equity). Under the Regulatory
Flexibility Act, if a rule has a significant economic impact on a
substantial number of small entities, an agency must analyze regulatory
options that would minimize any significant impact of the rule on small
entities. Section 202(a) of the Unfunded Mandates Reform Act of 1995
requires that agencies prepare a written statement of anticipated costs
and benefits before proposing any rule that may result in an
expenditure in any one year by State, local, and tribal governments, in
the aggregate, or by the private sector, of $100 million (adjusted
annually for inflation).
The agency believes that this final rule is consistent with the
principles set out in Executive Order 12866 and in these two statutes.
FDA has determined that the final rule is not a significant regulatory
action as defined by the Executive order and so is not subject to
review under the Executive order. As explained later in this section,
FDA concludes that the final rule will not have a significant economic
impact on a substantial number of small entities. The Unfunded Mandates
Reform Act
[[Page 24348]]
does not require FDA to prepare a statement of costs and benefits for
this final rule, because the rule is not expected to result in any 1-
year expenditure that would exceed $100 million adjusted for inflation.
The current inflation adjusted statutory threshold is about $110
million.
The purpose of this final rule is to establish a monograph for
ingrown toenail relief drug products for OTC human use and include
sodium sulfide 1 percent in a gel vehicle in the monograph. This final
rule provides for OTC availability of this type of product.
Manufacturers who wish to market this type of product have the
standard costs associated with the introduction of any new product.
These include preparation of labeling, stability testing, and
implementing manufacturing procedures. Any cost incurred will be
voluntary if manufacturers elect to market this type of product. This
cost may vary from manufacturer to manufacturer; however, the burden on
small manufacturers is not greater than that for large manufacturers.
Manufacturers will not incur any costs related to proving safety and
effectiveness of the active ingredient for this intended use.
Under the Regulatory Flexibility Act, if a rule has a significant
impact on a substantial number of small entities, an agency must
analyze regulatory options that would minimize any significant impact
of a rule on small entities. This final rule allows manufacturers to
market OTC ingrown toenail relief drug products containing sodium
sulfide 1 percent in a gel vehicle without having to obtain an approved
new drug application, as is currently required, and is beneficial to
small entities. Thus, this final rule will not impose a significant
economic burden on affected entities. Therefore, under the Regulatory
Flexibility Act, the agency certifies that the final rule will not have
a significant economic impact on a substantial number of small
entities. No further analysis is required.
V. Paperwork Reduction Act of 1995
FDA concludes that the labeling requirements in this document are
not subject to review by the Office of Management and Budget because
they do not constitute a ``collection of information'' under the
Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.). Rather, the
labeling statements are a ``public disclosure of information originally
supplied by the Federal Government to the recipient for the purpose of
disclosure to the public'' (5 CFR 1320.3(c)(2)).
VI. Environmental Impact
The agency has determined under 21 CFR 25.31(a) that this action is
of a type that does not individually or cumulatively have a significant
effect on the human environment. Therefore, neither an environmental
assessment nor an environmental impact statement is required.
VII. Federalism
FDA has analyzed this final rule in accordance with the principles
set forth in Executive Order 13132. FDA has determined that the rule
does not contain policies that have substantial direct effects on the
States, on the relationship between the National Government and the
States, or on the distribution of power and responsibilities among the
various levels of government. Accordingly, the agency has concluded
that the rule does not contain policies that have federalism
implications as defined in the Executive order and, consequently, a
federalism summary impact statement is not required.
List of Subjects
21 CFR Part 310
Administrative practice and procedure, Drugs, Labeling, Medical
devices, Reporting and recordkeeping requirements.
21 CFR Part 358
Labeling, Over-the-counter drugs.
0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs, 21 CFR parts
310 and 358 are amended as follows:
PART 310--NEW DRUGS
0
1. The authority citation for 21 CFR part 310 continues to read as
follows:
Authority: 21 U.S.C. 321, 331, 351, 352, 353, 355, 360b-360f,
360j, 361(a), 371, 374, 375, 379e; 42 U.S.C. 216, 241, 242(a), 262,
263b-263n.
0
2. Section 310.538 is amended by removing the ingredient sodium sulfide
in paragraph (a) and by adding paragraph (e) to read as follows:
Sec. 310.538 Drug products containing active ingredients offered
over-the-counter (OTC) for use for ingrown toenail relief.
* * * * *
(e) This section does not apply to sodium sulfide labeled,
represented, or promoted for OTC topical use for ingrown toenail relief
in accordance with part 358, subpart D of this chapter, after June 6,
2003.
PART 358--MISCELLANEOUS EXTERNAL DRUG PRODUCTS FOR OVER-THE-COUNTER
HUMAN USE
3. The authority citation for 21 CFR part 358 continues to read as
follows:
Authority: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371.
0
4. Part 358 is amended by adding new subpart D, consisting of
Sec. Sec. 358.301 to 358.350, to read as follows:
Subpart D--Ingrown Toenail Relief Drug Products
Sec.
358.301 Scope.
358.303 Definitions.
358.310 Ingrown toenail relief active ingredient.
358.350 Labeling of ingrown toenail relief drug products.
Subpart D--Ingrown Toenail Relief Drug Products
Sec. 358.301 Scope.
(a) An over-the-counter ingrown toenail relief drug product in a
form suitable for topical administration is generally recognized as
safe and effective and is not misbranded if it meets each condition in
this subpart and each general condition established in Sec. 330.1 of
this chapter.
(b) References in this subpart to regulatory sections of the Code
of Federal Regulations are to chapter 1 of title 21 unless otherwise
noted.
Sec. 358.303 Definitions.
As used in this subpart:
(a) Ingrown toenail relief drug product. A drug product applied to
an ingrown toenail that relieves pain or discomfort either by softening
the nail or by hardening the nail bed.
(b) Retainer ring. A die cut polyethylene foam pad coated on one
side with medical grade acrylic pressure-sensitive adhesive. The
retainer ring has slots, center-cut completely through the foam with
the cut of sufficient size to allow for localization of an active
ingredient in a gel vehicle to a specific target area. The retainer
ring is used with adhesive bandage strips to place over the retainer
ring to hold it in place.
Sec. 358.310 Ingrown toenail relief active ingredient.
The active ingredient of the product is sodium sulfide 1 percent in
a gel vehicle. The gel vehicle is an aqueous, semisolid system with
large organic molecules interpenetrated with a liquid.
Sec. 358.350 Labeling of ingrown toenail relief drug products.
(a) Statement of identity. The labeling of the product contains the
established
[[Page 24349]]
name of the product, if any, and identifies the product as an ``ingrown
toenail relief product'' or as an ``ingrown toenail discomfort
reliever.''
(b) Indications. The labeling of the product states, under the
heading ``Use,'' the following: ``for temporary relief of'' [select one
or both of the following: 'pain' or 'discomfort'] ``from ingrown
toenails''. Other truthful and nonmisleading statements, describing
only the use that has been established and listed in this paragraph
(b), may also be used, as provided in Sec. 330.1(c)(2) of this
chapter, subject to the provisions of section 502 of the Federal Food,
Drug, and Cosmetic Act (the act) relating to misbranding and the
prohibition in section 301(d) of the act against the introduction or
delivery for introduction into interstate commerce of unapproved new
drugs in violation of section 505(a) of the act.
(c) Warnings. The labeling of the product contains the following
warnings under the heading ``Warnings'':
(1) ``For external use only'' in accord with Sec. 201.66(c)(5)(i)
of this chapter.
(2) ``Do not use [bullet]\1\ on open sores''.
---------------------------------------------------------------------------
\1\See Sec. 201.66(b)(4) of this chapter for definition of
bullet.
---------------------------------------------------------------------------
(3) ``Ask a doctor before use if you have [bullet] diabetes
[bullet] poor circulation [bullet] gout''.
(4) ``When using this product [bullet] use with a retainer ring''.
(5) ``Stop use and ask a doctor if [bullet] redness or swelling of
your toe increases [bullet] discharge is present around the nail
[bullet] symptoms last more than 7 days or clear up and occur again
within a few days''.
(d) Directions. The labeling of the product contains the following
statements under the heading ``Directions'':
(1) ``[Bullet] adults and children 12 years and over:''
(i) ``[Bullet] wash the affected area and dry thoroughly [bullet]
place retainer ring on toe with slot over the area where the ingrown
nail and the skin meet. Smooth ring down firmly. [bullet] apply enough
gel product to fill the slot in the ring [bullet] place round center
section of bandage strip directly over the gel-filled ring to seal the
gel in place. Smooth ends of bandage strip around toes.''
(ii) ``[Bullet] repeat twice daily (morning and night) for up to 7
days until discomfort is relieved or until the nail can be lifted out
of the nail groove and easily trimmed''.
(2) ``[Bullet] children under 12 years: ask a doctor''.
Dated: April 23, 2003.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 03-11285 Filed 5-6-03; 8:45 am]
BILLING CODE 4160-01-S